Atlas Trials

Akt Inhibitor MK2206, Lapatinib Ditosylate, and Trastuzumab in Treating Patients With Locally Advanced or Metastatic HER2-Positive Breast , Gastric, or Gastroesophageal Cancer That Cannot Be Removed By Surgery

Clinical trial NCT01705340 · TERMINATED

Trial details

NCT number
NCT01705340
Sponsor
National Cancer Institute (NCI)
Status
TERMINATED
Phase
Phase 1
Study type
INTERVENTIONAL
Adenocarcinoma of the Gastroesophageal JunctionHER2-positive Breast CancerMale Breast CancerRecurrent Breast CancerRecurrent Esophageal CancerRecurrent Gastric CancerStage IIIC Breast CancerStage IIIC Esophageal CancerStage IIIC Gastric CancerStage IV Breast CancerStage IV Esophageal CancerStage IV Gastric Cancer
Start date
2012-09-01
Primary completion
2013-05-01
Enrollment
60

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.